MetaVia is trading at $1.25, down -9.42%, with no confirmed company-specific news explaining the October 26 decline. - The latest identified company announcement was the October 13 appointment of a chief medical officer. - Major U.S. indexes were higher, so broad-market weakness does not explain the stock’s opposite-direction move; the cause remains unclear. - The supplied information does not include current trading volume.